Do I Qualify for the Medicare GLP-1 Bridge Program?

The useful distinction is this: Part D coverage is coverage for a drug when Medicare already recognizes a covered indication. Bridge coverage is a separate, time-limited route for certain obesity-treatment cases that would otherwise fall outside that flow. That distinction prevents the most common mistake: assuming that every Medicare beneficiary seeking a GLP-1 medicine starts with the Bridge.

Do I qualify for the Medicare GLP-1 Bridge program?

You qualify only if both the coverage rules and the clinical rules line up. According to CMS's 2026 provider guidance, eligible coverage includes standalone Part D plans and Medicare Advantage coordinated-care plans with drug coverage; certain SNPs, employer or union group waiver plans, and LI NET are also included.

The program is not an alternative for someone who already has Part D coverage for a GLP-1 medicine. CMS states in 2026 that people with type 2 diabetes, moderate-to-severe obstructive sleep apnea, or noncirrhotic MASH are not eligible for Bridge when their GLP-1 use is Part D-coverable. The same principle applies to people already receiving GLP-1 coverage through Part D.

Eligibility is measured at treatment initiation, not necessarily at the moment the prior authorization is reviewed. CMS gives a 2026 example of a person with a BMI of 37 when therapy begins who has a BMI of 34 when Bridge prior authorization is requested; that person can still meet the BMI-at-least-35 route. Keep records that establish the starting clinical picture, because that is the decision point CMS identifies.

Which weight-loss drugs are available for $50 through Medicare?

The Bridge covers Foundayo tablets, Wegovy injection or tablets, and Zepbound KwikPen, according to Medicare.gov's 2026 Bridge coverage page. Single-dose Zepbound pens and vials are excluded, so the product form matters as much as the medicine name.

The beneficiary copay is $50 for a 28- or 30-day supply, according to Medicare.gov in 2026. CMS states in 2026 that participating manufacturers provide eligible Bridge medicines at a net price of $245 per monthly supply, but the patient-facing rule is more important for budgeting: the $50 remains the same regardless of the beneficiary's Part D benefit phase.

This is separate-program spending. As Medicare.gov explains in 2026, the copay does not count toward the yearly Part D deductible or out-of-pocket limit. CMS confirms in 2026 that neither the $245 net price nor the $50 copay is treated as Part D true out-of-pocket spending. Extra Help cannot lower the $50 copay, and the Medicare Prescription Payment Program cannot be used for Bridge drugs, according to CMS in 2026.

That can feel counterintuitive because a predictable copay is not the same thing as progress toward Part D cost protection. For another example of why Medicare coverage depends on the particular service and benefit rules, see Does Medicare Cover Multifocal Lenses for Cataract Surgery?.

What BMI and health conditions do I need to qualify?

You need one of three clinical routes at the start of GLP-1 therapy, according to Medicare.gov in 2026. The program uses BMI thresholds paired with specific conditions rather than a broad statement that obesity alone always qualifies.

These routes are narrow by design. A BMI that meets one threshold without the condition required for that route does not establish eligibility under the published criteria. Likewise, a listed condition without the necessary BMI threshold does not establish eligibility. The practical task is to compare the clinical record at initiation against one complete row, not to assemble pieces from different rows.

Scale also helps explain why precision matters. KFF estimated in 2023 that 9.7 million of 47.5 million Part D enrollees met the clinical criteria, yet 3.8 million, or 39% of that clinical group, could meet all Bridge eligibility criteria. Meeting the health criteria and meeting the full program rules are different tests.

How do the prescription and prior-authorization steps work?

The process has four handoffs: prescriber, pharmacy, Bridge eligibility review, and prior authorization. CMS's 2026 prescriber fact sheet directs the clinician to send the prescription through the normal pharmacy process with an obesity diagnosis code from the E66 family and the electronic-note instruction “SEND TO BRIDGE FOR WEIGHT MANAGEMENT.”

1. The prescriber writes the prescription and certifies that treatment is part of a diet-and-exercise lifestyle program, as Medicare.gov requires in 2026.
2. The pharmacy submits the claim to Bridge, where Medicare checks eligibility, according to CMS in 2026.
3. For an eligible person receiving a covered drug, the initial claim is denied because prior authorization is required; CMS says in 2026 that the pharmacy typically sends the request to the prescriber within 24 to 72 hours.
4. The prescriber completes the authorization electronically or by fax. CMS states in 2026 that it strongly encourages electronic submission and sends the approval or denial to the patient by mail and to the provider through the portal or fax within 72 hours of submission.

If no request arrives within 72 hours, CMS directs the prescriber in 2026 to download and submit the Bridge fax form. Once a first fill is approved, CMS says in 2026 that refills and dose changes do not need a new authorization unless the person changes to another covered GLP-1 drug. Approval does not extend beyond December 31, 2027, when the demonstration ends, according to CMS in 2026.